BioDelivery Sciences International (BDSI) : During the past 4 weeks, traders have been relatively bearish on BioDelivery Sciences International (BDSI), hence the stock is down -6.59% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.55% relative to the S&P 500. The 4-week change in the price of the stock is -4.26% and the stock has fallen -3.14% in the past 1 week.
BioDelivery Sciences International (NASDAQ:BDSI): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.46 and $2.42 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.51. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.47, notching a gain of 0.82% for the day. The total traded volume was 250,992 . The stock had closed at $2.45 on the previous day.
The stock has recorded a 20-day Moving Average of 0.06% and the 50-Day Moving Average is 1.97%. BioDelivery Sciences International, Inc. is up 7.39% in the last 3-month period. Year-to-Date the stock performance stands at -48.43%.
BioDelivery Sciences International (BDSI) has been rated by 7 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $16 and the lowest price target forecast is $4. The average forecast of all the analysts is $7.43 and the expected standard deviation is $4.2.
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.